About 13 results found for searched term "EC330" (0.126 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14696 | EC330 | Others |
| EC330 is a leukemia inhibitory factor (LIF) inhibitor. EC330 blocked formation of colonies in soft agar and inhibited angiogenesis (tube formation) in human umbilical vein endothelial cells. | ||
| M2215 | Niraparib (MK-4827) | PARP |
| MK-4827 | ||
| MK-4827 (Niraparib) is a selective PARP1/2 inhibitor with an IC50 value of 3.8 nM/2.1 nM that increases the formation of PARP-DNA complexes through inhibition of PARPase activity, leading to DNA damage, apoptosis, PARP-1-dependent cell death (parthanatos) and cell death. Strong effector activity when acting on cancer cells harboring mutant BRCA-1 and BRCA-2. It is more than 330-fold more selective than PARP3, V-PARP and Tank1. | ||
| M6849 | JNJ 63533054 | GPR/FFAR |
| JNJ-63533054 is a potent, selective, orally active GPR139 agonist.JNJ-63533054 is more selective for GPR139 than other GPCR, ion channel and transporter proteins.JNJ-63533054 can cross the blood-brain barrier (BBB). | ||
| M7936 | Mephetyl tetrazole | Potassium Channel |
| Mephetyl tetrazole is a potent, selective Kv1.5 potassium channel blocker with an IC50 value of 330 nM that selectively prolongs atrial effective response period (ERP) but has no effect on ventricular ERP. | ||
| M8594 | BRD3308 | HDAC |
| BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23 times more selective to HDAC3 than HDAC1 (IC50:1.26 μM) or HDAC2 (IC50:1.34 μM). BRD3308 inhibits pancreatic β cell apoptosis induced by inflammatory cytokines or glucolipid toxic stress and increases functional insulin release. BRD3308 also activates HIV-1 transcription and disrupts HIV-1 latency. | ||
| M10332 | Vapreotide acetate | Neurokinin Receptor |
| BMY-41606; RC160; Octastatin acetate | ||
| Vapreotide acetate (BMY-41606 acetate; RC160 acetate) is a neurokinin-1 (NK1) receptor antagonist with IC50 value of 330 nM. | ||
| M27671 | Vapreotide | Neurokinin Receptor |
| RC160; BMY 41606 | ||
| Vapreotide is a neurokinin-1 (NK1) receptor antagonist, with an IC50 of 330 nM. | ||
| M29509 | SRI-37330 | Others |
| SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes. | ||
| M29510 | SRI-37330 hydrochloride | Others |
| SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research. | ||
| M30062 | CMPD1 | p38 MAPK |
| CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM. | ||
| M30147 | TC OT 39 | Oxytocin Receptor |
| TC OT 39 is a synthetic oxytocin analog, as well as a selective agonist of oxytocin receptor (OXTR, EC50=180 nM). TC OT 39 is also an Avprla vasopressin receptor antagonist with an Ki value of 330 nM. TC OT 39 exhibits sedative effects in mouse models. | ||
| M54084 | Boc-D-Leucine monohydrate | Amino Acid Derivatives |
| Boc-D-Leucine monohydrate (Boc-D-Leu-OH hydrate) is an N-Boc-protected form of D-Leucine (L330150). | ||
| M54523 | NMS-03305293 | PARP |
| NMS-293 | ||
| NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
